Stockreport

MindMed Reports Q2 2025 Financial Results and Business Updates

Mind Medicine (MindMed) Inc. - Common Shares  (MNMD) 
PDF --Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder [Read more]